Light Chain Amyloidosis

Patient Experience Survey from the Amyloidosis Research Consortium

Isabelle Lousada, Raymond L. Comenzo, Heather Landau, Spencer Guthrie, Giampaolo Merlini

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Introduction: Information detailing the experience of patients with light chain (AL) amyloidosis is lacking. The primary aim of this study was to gather data on the patient experience to understand the challenges in diagnosis and to gain insight into barriers to accessing appropriate care. Methods: Patients with amyloidosis, family members, and caregivers were invited to participate in an online 16-question survey (available from January 29 to February 5, 2015). Participants with AL amyloidosis were sent an eight-question follow-up survey. Results: The initial survey was completed by 533 participants (follow-up survey completed by 201 participants). AL amyloidosis was the most common diagnosis. For 37.1% of respondents, the diagnosis of amyloidosis was not established until ≥1 year after the onset of initial symptoms. Diagnosis was received after visits to 1, 2, 3, 4, or ≥5 physicians by 7.6%, 23.5%, 20.3%, 16.8%, and 31.8% of respondents, respectively. Correct diagnosis was most often made by hematologists/oncologists (34.1%). Treatments included chemotherapy (63.1%) and stem cell transplantation (38.9%) and were difficult to tolerate for 54.1% of respondents. A significant number of respondents felt uninformed about clinical trials. Nevertheless, approximately half (46.1%) believed that enrolling in a trial would enhance their care. Conclusions: Establishing a diagnosis of amyloidosis is difficult. Current treatments are difficult to tolerate and do not substantially improve quality of life for most patients. There is an urgent need for well-tolerated therapies with clear treatment benefit. Patient awareness of clinical trials can be improved, especially given that respondents indicated high willingness to participate.

Original languageEnglish
Pages (from-to)920-928
Number of pages9
JournalAdvances in Therapy
Volume32
Issue number10
DOIs
Publication statusPublished - Oct 1 2015

Fingerprint

Amyloidosis
Light
Research
Clinical Trials
Surveys and Questionnaires
Stem Cell Transplantation
Therapeutics
Caregivers
Quality of Life
Physicians
Drug Therapy

Keywords

  • Disease awareness
  • Early diagnosis
  • Patient survey
  • Systemic amyloidosis
  • Treatment

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Light Chain Amyloidosis : Patient Experience Survey from the Amyloidosis Research Consortium. / Lousada, Isabelle; Comenzo, Raymond L.; Landau, Heather; Guthrie, Spencer; Merlini, Giampaolo.

In: Advances in Therapy, Vol. 32, No. 10, 01.10.2015, p. 920-928.

Research output: Contribution to journalArticle

Lousada, Isabelle ; Comenzo, Raymond L. ; Landau, Heather ; Guthrie, Spencer ; Merlini, Giampaolo. / Light Chain Amyloidosis : Patient Experience Survey from the Amyloidosis Research Consortium. In: Advances in Therapy. 2015 ; Vol. 32, No. 10. pp. 920-928.
@article{e0ae903bf05640afa25721c4b5e13504,
title = "Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium",
abstract = "Introduction: Information detailing the experience of patients with light chain (AL) amyloidosis is lacking. The primary aim of this study was to gather data on the patient experience to understand the challenges in diagnosis and to gain insight into barriers to accessing appropriate care. Methods: Patients with amyloidosis, family members, and caregivers were invited to participate in an online 16-question survey (available from January 29 to February 5, 2015). Participants with AL amyloidosis were sent an eight-question follow-up survey. Results: The initial survey was completed by 533 participants (follow-up survey completed by 201 participants). AL amyloidosis was the most common diagnosis. For 37.1{\%} of respondents, the diagnosis of amyloidosis was not established until ≥1 year after the onset of initial symptoms. Diagnosis was received after visits to 1, 2, 3, 4, or ≥5 physicians by 7.6{\%}, 23.5{\%}, 20.3{\%}, 16.8{\%}, and 31.8{\%} of respondents, respectively. Correct diagnosis was most often made by hematologists/oncologists (34.1{\%}). Treatments included chemotherapy (63.1{\%}) and stem cell transplantation (38.9{\%}) and were difficult to tolerate for 54.1{\%} of respondents. A significant number of respondents felt uninformed about clinical trials. Nevertheless, approximately half (46.1{\%}) believed that enrolling in a trial would enhance their care. Conclusions: Establishing a diagnosis of amyloidosis is difficult. Current treatments are difficult to tolerate and do not substantially improve quality of life for most patients. There is an urgent need for well-tolerated therapies with clear treatment benefit. Patient awareness of clinical trials can be improved, especially given that respondents indicated high willingness to participate.",
keywords = "Disease awareness, Early diagnosis, Patient survey, Systemic amyloidosis, Treatment",
author = "Isabelle Lousada and Comenzo, {Raymond L.} and Heather Landau and Spencer Guthrie and Giampaolo Merlini",
year = "2015",
month = "10",
day = "1",
doi = "10.1007/s12325-015-0250-0",
language = "English",
volume = "32",
pages = "920--928",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer Healthcare",
number = "10",

}

TY - JOUR

T1 - Light Chain Amyloidosis

T2 - Patient Experience Survey from the Amyloidosis Research Consortium

AU - Lousada, Isabelle

AU - Comenzo, Raymond L.

AU - Landau, Heather

AU - Guthrie, Spencer

AU - Merlini, Giampaolo

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Introduction: Information detailing the experience of patients with light chain (AL) amyloidosis is lacking. The primary aim of this study was to gather data on the patient experience to understand the challenges in diagnosis and to gain insight into barriers to accessing appropriate care. Methods: Patients with amyloidosis, family members, and caregivers were invited to participate in an online 16-question survey (available from January 29 to February 5, 2015). Participants with AL amyloidosis were sent an eight-question follow-up survey. Results: The initial survey was completed by 533 participants (follow-up survey completed by 201 participants). AL amyloidosis was the most common diagnosis. For 37.1% of respondents, the diagnosis of amyloidosis was not established until ≥1 year after the onset of initial symptoms. Diagnosis was received after visits to 1, 2, 3, 4, or ≥5 physicians by 7.6%, 23.5%, 20.3%, 16.8%, and 31.8% of respondents, respectively. Correct diagnosis was most often made by hematologists/oncologists (34.1%). Treatments included chemotherapy (63.1%) and stem cell transplantation (38.9%) and were difficult to tolerate for 54.1% of respondents. A significant number of respondents felt uninformed about clinical trials. Nevertheless, approximately half (46.1%) believed that enrolling in a trial would enhance their care. Conclusions: Establishing a diagnosis of amyloidosis is difficult. Current treatments are difficult to tolerate and do not substantially improve quality of life for most patients. There is an urgent need for well-tolerated therapies with clear treatment benefit. Patient awareness of clinical trials can be improved, especially given that respondents indicated high willingness to participate.

AB - Introduction: Information detailing the experience of patients with light chain (AL) amyloidosis is lacking. The primary aim of this study was to gather data on the patient experience to understand the challenges in diagnosis and to gain insight into barriers to accessing appropriate care. Methods: Patients with amyloidosis, family members, and caregivers were invited to participate in an online 16-question survey (available from January 29 to February 5, 2015). Participants with AL amyloidosis were sent an eight-question follow-up survey. Results: The initial survey was completed by 533 participants (follow-up survey completed by 201 participants). AL amyloidosis was the most common diagnosis. For 37.1% of respondents, the diagnosis of amyloidosis was not established until ≥1 year after the onset of initial symptoms. Diagnosis was received after visits to 1, 2, 3, 4, or ≥5 physicians by 7.6%, 23.5%, 20.3%, 16.8%, and 31.8% of respondents, respectively. Correct diagnosis was most often made by hematologists/oncologists (34.1%). Treatments included chemotherapy (63.1%) and stem cell transplantation (38.9%) and were difficult to tolerate for 54.1% of respondents. A significant number of respondents felt uninformed about clinical trials. Nevertheless, approximately half (46.1%) believed that enrolling in a trial would enhance their care. Conclusions: Establishing a diagnosis of amyloidosis is difficult. Current treatments are difficult to tolerate and do not substantially improve quality of life for most patients. There is an urgent need for well-tolerated therapies with clear treatment benefit. Patient awareness of clinical trials can be improved, especially given that respondents indicated high willingness to participate.

KW - Disease awareness

KW - Early diagnosis

KW - Patient survey

KW - Systemic amyloidosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84946496097&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946496097&partnerID=8YFLogxK

U2 - 10.1007/s12325-015-0250-0

DO - 10.1007/s12325-015-0250-0

M3 - Article

VL - 32

SP - 920

EP - 928

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 10

ER -